Psychedelics stocks are becoming more popular as more research goes into them. Here are 3 stock ideas for your watchlist.

Helus Pharma CEO Michael Halstead said the company is preparing for a potentially pivotal period as it expects top-line results in the fourth quarter from its first Phase III trial of HLP003 as an adjunctive treatment for major depressive disorder. Speaking at a Canaccord Genuity event, Halstead, w

Cybin (HELP) is in focus after Helus Pharma appointed Michael Halstead as Chief Executive Officer on 3 August 2026. He brings 25 years of pharmaceutical leadership across product launches, capital markets and major corporate transactions. See our latest analysis for Cybin. The CEO appointment has come alongside sharp share price momentum for Cybin, with a 7 day share price return of 48.47% and a 90 day share price return of 118.64%, although the 5 year total shareholder return is down...

In August 2026, Helus Pharma appointed Michael Halstead as Chief Executive Officer, bringing 25 years of biopharma experience including leadership roles in major acquisitions and the commercialization of CAPLYTA® across several psychiatric indications. Halstead’s history of helping transform clinical-stage companies into fully integrated commercial organizations, while overseeing large equity offerings and multi‑billion‑dollar sales, is a meaningful reference point for Cybin’s own late‑stage...

Cybin’s updated analyst model features a reduced fair value estimate, with the price target moving from US$49.46 to US$37.57, a cut of about 24% in the projected equity value per share. This change sits against a backdrop of mixed sector commentary on psychedelic drug developers, where optimism around potential pharma deals and regulatory clarity is balanced by caution on valuation resets and deal outcomes. As you read on, you will see how these shifting assumptions feed into the evolving...

Watch Fireside Chat Below, or Click HERE: IPO Edge hosted a fireside chat with Jupiter Neurosciences, Inc. (Nasdaq: JUNS) Chairman, Chief Executive Officer and Co-founder Christer Rosén and Alison Silva, […]

Cybin, operating as Helus Pharma, has advanced its lead psychedelic candidate HLP003 into an ongoing Phase 3 trial for adjunctive treatment of major depressive disorder and recently completed an underwritten public offering raising about US$50,000,000 to fund development. This combination of late-stage clinical progress and fresh capital support highlights how Cybin is positioning HLP003 as a potential clinic-based mental health therapy within its broader psychedelic treatment...

Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could see a positive read-through after Johnson & Johnson (NYSE:JNJ) reported stronger second-quarter sales for its Spravato depression...

We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Cybin D/B/A Helus Pharma (NASDAQ:HELP) is one of the best psychedelic stocks on our list. TheFly reported on July 1 that Canaccord analyst Sumant Kulkarni lowered the price target on HELP to $42 from $45 while maintaining a Buy rating […]

The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Jefferies said could benefit companies including Compass Pathways (NASDAQ:CMPS), AtaiBeckley Inc....